Efficacy and safety of topical 0.5% 5-Fluorouracil as primary treatment of ocular surface squamous neoplasia.

OBJECTIVE: To assess the efficacy and safety of topical 0.5% 5-Fluorouracil (5-FU) as a primary therapy of ocular surface squamous neoplasia (OSSN). DESIGN: Retrospective study. PARTICIPANTS: Patients with clinically suspected OSSN referred to a Brazilian tertiary health center between October 2015 and December 2022. METHODS: After diagnostic confirmation of OSSN with exfoliative cytology, 0.5% 5-FU was administered topically 4 times daily for 2 weeks followed by a pause of 2 weeks. RESULTS: A total of 54 patients were included in this study, 32 males (59.3%), mean age of 62.9 years old. Complete resolution of OSSN was achieved in 70.4%. The median number of cycles was 2 (range 1-5). Side effects were reported in 35.2%, which included eyelid erythema, conjunctival hyperemia, and punctal stenosis. None of the patients stopped treatment due to adverse effects. Patients who had partial response to 0.5% 5-FU had complementary treatment with surgery, Mitomycin-C and/or Interferon ⍺2b. Overall recurrence was 14.8%. Median follow-up was 14 months (range 2-92 months). In a multivariate Cox regression analysis, the risk of relapse was 84% lower in patients who had complete response to 0.5% 5-FU (p = 0.018). CONCLUSION: Topical 0.5% 5-FU may be considered a safe and effective primary therapy for OSSN, with a low rate of side effects.

Corneal and Coronary Calcification in Maintenance Hemodialysis: The Face Is No Index to the Heart.

Although the eyes are the main site of metastatic calcification in patients with chronic kidney disease (CKD), corneal and conjunctival calcification (CCC) is poorly evaluated in this population. Whether CCC correlates with coronary artery calcification remains unknown since studies so far have relied on methods with low sensitivity. Our objective was to test the relationship between CCC and coronary calcification based on tomography. This was a cross-sectional study that included patients on maintenance dialysis. Clinical, demographic, and biochemical data (calcium, phosphorus, parathormone, alkaline phosphatase, and 25(OH)-vitamin D) were recorded. Hyperparathyroidism was defined as parathyroid hormone (PTH) > 300 pg/mL. CCC was evaluated by anterior segment optical coherence tomography (AS-OCT), and coronary calcium scores (Agatston method) were assessed by computed tomography. We compared no/mild with moderate/severe CCC. Twenty-nine patients were included (49.6 ± 15.0 years, 62.1% female, on hemodialysis for 5.7 [2.7-9.4] years, 17.2% with diabetes mellitus, 75.9% with hyperparathyroidism). CCC was found in 82.7% of patients, with median scores of 9 (3, 14.5), ranging from 0 to 16. CCC was classified as absent/mild, moderate, and severe in 27.6%, 20.7%, and 51.7%, respectively. Coronary calcification was found in 44.8% of patients, with median scores of 11 (0, 464), varying from 0 and 6456. We found no significant correlation between coronary calcium scores and CCC (r = 0.203, p = 0.282). Hyperphosphatemia was more frequent in patients with moderate/severe CCC than in those with absent/mild CCC. We concluded that CCC was frequent in patients with CKD on dialysis and did not correlate with coronary calcium scores. Hyperphosphatemia appears to contribute to CCC. © 2023 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.

Corneal and Conjunctival Calcification in a Dialysis Patient Reversed by Parathyroidectomy.

Mineral and bone metabolism disorders are relatively common among patients with end-stage renal disease on maintenance hemodialysis. Corneal and conjunctival calcification is the main extravascular site for calcification. Recently, this form of calcification has been linked to vascular calcification. Secondary hyperparathyroidism can lead to high levels of calcium and phosphorus and increase the risk of calcification. Here, we report a case of a 38-year-old female with severe hyperparathyroidism who underwent eye examination before and after parathyroidectomy. Anterior segment optical coherence tomography showed an improvement in the number and size of ocular calcifications 6 months after surgery. This case calls attention to the importance of eye examination in patients on dialysis and brings the possibility of recovery of calcification in a short-term follow-up.

Dry eye in rheumatoid arthritis patients under TNF-inhibitors: conjunctival goblet cell as an early ocular biomarker.

Dry eye disease (DED) is common in Rheumatoid Arthritis (RA) patients. The application of conjunctival goblet cell count as a clinical biomarker to diagnose and respond to treatment can take place in rheumatoid arthritis patients under TNF-inhibitors (TNFi) therapy. This study aimed to investigate the ocular surface parameters and the long-term effects of TNFi therapy on ocular surface features and goblet cell count of rheumatoid arthritis patients. At baseline, rheumatoid arthritis patients eligible to TNFi were compared to healthy controls (similar age/gender), regarding Ocular Surface Disease Index (OSDI) questionnaire, Schirmer I test, tear break-up time test, vital dye staining of the ocular surface, and conjunctival impression cytology. DED severity grade, impression cytology score, and goblet cell count were analyzed. Rheumatoid arthritis patients were followed after three (3 M) and 12 months (12 M), during TNFi treatment. Sixteen rheumatoid arthritis patients and 24 controls were compared: a higher frequency of abnormal OSDI (68.8% vs. 16.7%, p = 0.002), Schirmer's test < 10 mm (37.5% vs. 8.3%, p = 0.042), meibomian gland dysfunction (50% vs. 8.3%, p = 0.007), abnormal impression cytology (75% vs. 8.3%, p < 0.001), and mild to moderate DED (81.3% vs. 4.2%, p < 0.001) were observed in rheumatoid arthritis patients, who also had lower goblet cell count [325 (274-707) cells/mm2 vs. 742 (562-863) cells/mm2, p = 0.004]. The presence of Meibomian gland dysfunction was associated with higher disease activity scores (p < 0.05). The prospective early observation of these patients at 3 M showed an increase improvement in tear production by Schirmer's test [13 (7.5-17.5) vs. 23.5 (16-35); p = 0.001], and an improvement in impression cytology score [1 (0.5-2) vs. 1 (0-1), p = 0.031] and in goblet cell count [325 (274-707) vs. 931 (656-1,244), p < 0.001]. Eight RA responders to TNFi were also re-evaluated at 12 M with further improvement in goblet cell count [393 (275-827) vs. 872 (502-1,185) vs. 1,079 (867-1,244), p = 0.047]. Multifactorial DED is frequent in RA patients, comprising aqueous, lipid, and mucin components. TNFi prompt improves tear production and recovers the goblet cells, which can be a biomarker of the pathological process and response to therapy in this population.

Improvement of conjunctival cytological grade and tear production in Ankylosing Spondylitis patients under TNF inhibitors: a long-term follow-up.

Dry eye disease can compromise the patient's quality of life. Few studies assessed the ocular surface (OS) in Ankylosing Spondylitis (AS) patients. This study aimed to evaluate the clinical and cytological findings of the OS in patients with AS, classify dry eye disease (DED) severity grade and conjunctival impression cytology (IC), and the effects of TNF inhibitors (TNFi) in a one-year follow-up. A baseline (BL) evaluation included 36 AS patients and 39 healthy controls. They fulfilled the Ocular Surface Index Disease questionnaire and underwent the Schirmer I test, break-up time, vital staining, and conjunctival IC. A DED severity grade, as well as IC rating, was applied. Fourteen of these patients received TNFi and analysis of ocular and systemic AS disease parameters occurred at BL and three months (3 M), and 12 months (12 M) after treatment. The AS patients presented a higher frequency of DED (p = 0.01), a worse score of severity (p = 0.001), and a higher frequency of altered IC (p = 0.007) when compared to controls. The 14 patients under TNFi presented an improvement in all the clinical disease activity parameters throughout the one-year treatment (p < 0.05) even as a concomitant increase in the Schirmer test (p = 0.04), and a significant amelioration in the altered IC to a normal IC (p = 0.006). DED is a frequent and under-diagnosed ocular disease in AS patients. The long-term parallel improvement of disease activity and OS parameters in AS patients receiving TNFi suggests that the OS can be an additional target of systemic inflammation in AS.

Topical steroids eye drops in conjunctival reactive lymphoid hyperplasia: Case report.

RATIONALE: Conjunctival lymphoproliferative lesions constitute a significant diagnostic challenge and it is essential to exclude neoplastic lesions. Histopathological and immunohistochemical tests are very useful in establishing the correct diagnosis. Reactive lymphoid hyperplasia (RLH) is part of a spectrum of lymphocytic infiltrative disorders. Evidence is scarce regarding appropriate treatment of conjunctival RLH. We report a case treated with topical corticosteroid. PATIENT CONCERNS: A 40 year-old female presented with a 7-month history of a slow growth tumor in the superior conjunctiva of the right eye. Slit-lamp examination demonstrated salmon colored lesion in the upper conjunctiva, with little conjunctival injection, but no significant neovascularization. There was no eyelid involvement. DIAGNOSES: Ultrasound biomicroscopy showed lesion depth (1.53 mm) and larger diameter (10.73 mm). Pathological examination revealed a chronic inflammatory process with conjunctival folicular hyperplasia. The immunohistochemistry examination showed predominance of CD20, CD23, and CD 3 e CD 5. INTERVENTION: We started topic prednisolone 1% 6 times daily. OUTCOMES: Six months after starting treatment, the lesion completely resolved, without any side-effects or recurrence during three-year follow-up period. LESSONS: Conjunctival RLH can be managed in various ways, depending on patient symptonm, comorbities, and disease distribution. Surgical resection with cryotherapy, radiotherapy, systemic corticosteroids, subconjunctival triamcinolone, and rituximab are some options. There is no strong evidence in the literature of conjunctival RLH successfully treated with topical eye drops corticosteroid. In this report, we obtained completely resolution of conjunctival RLH with topical corticosteroid. CONCLUSION: Topical eye drops corticosteroids are an alternative treatment for selected cases of conjuncitval RLH with no orbital or eyelid involvement.

Perspectivas no tratamento da alergia ocular: revisão das principais estratégias terapêuticas / Ocular allergy therapy perspectives: Review on the main therapeutic targets

As alergias oculares englobam uma série de doenças inflamatórias da superfície ocular, causadas por diferentes mecanismos de hipersensibilidade. Acometem aproximadamente 20% da população e podem ser classificadas em formas mediadas por hipersensibilidade tipo I (CAS, CAP), tipo I e IV (CCV, CCA) e tipo IV (BCC, CPG). As formas mais prevalentes são CAS e CAP. As formas crônicas (CCV, CCA) estão mais frequentemente relacionadas a complicações e comprometimento da função visual decorrentes do processo inflamatório e consequente remodelação da superfície ocular. Comorbidades como olho seco e ceratocone podem estar presentes. O tratamento envolve diagnóstico e afastamento dos fatores etiológicos envolvidos, uso de drogas anti-inflamatórias que atuem na ação de linfócitos Th2, eosinófilos, mastócitos e células dendríticas Avanços no conhecimento da ativação e tráfego de células do sistema imune têm sido promissores na perspectiva de novas abordagens terapêuticas.

Ocular allergies encompass a number of inflammatory diseases in the ocular surface which have different hypersensitivity mechanisms and occur in 20% of population. They can be classified as being type I hypersensitivity mediated (PAC, SAC), type I and IV (VKC, AKC) and type IV (BKC, GPC). The most prevalent forms are PAC and SAC. The chronic presentations are mostly related to visual impairment due to remodeling in the ocular surface caused by chronic inflammation. Dry eye disease and keratoconus are comorbidities observed in severe cases. The management is based on accurate diagnosis, avoidance of etiological factors and the rational use of drugs that control the inflammatory events caused by Th2 driven. The advances in knowledge on activation and traffic of immune cells are providing new drugs and many perspectives on different approaches.

Treatment of Sjögren's syndrome dry eye using 0.03% tacrolimus eye drop: Prospective double-blind randomized study.

OBJECTIVE: To describe the clinical efficacy of the treatment of Sjögren's syndrome dry eye using 0.03% tacrolimus eye drop. DESIGN: Prospective double-blind randomized study. SETTING: Institutional outpatient clinic. PARTICIPANTS: Forty-eight eyes of twenty-four patients with dry eye related to Sjögren syndrome were enrolled in this study. The patients were randomized in 2 groups: tacrolimus (n=14) and vehicle (n=10) group. INTERVENTION: The tacrolimus group received a vial containing tacrolimus 0.03% (almond oil as vehicle) and the other group received the almond oil vehicle. All patients were instructed to use the eye drops every 12h in the lower conjunctival sac. MAIN OUTCOME MEASURES: Schirmer I test, break-up-time (BUT), corneal fluorescein and Rose Bengal staining scores were evaluated in all patients one day before the treatment (baseline), 7, 14, 28 and 90 days after treatment with the eye drops. RESULTS: The average fluorescein and Rose Bengal scores improved statistically after 7 days of treatment and even more after 90 days. The average Schirmer I and BUT values were unchanged after 7, 14 and 21 days but did show an improvement relative to baseline after 28 days of treatment. Schirmer I, BUT, fluorescein and Rose Bengal did not show any statistical significance in the vehicle group. CONCLUSION: Topical 0.03% tacrolimus eye drop improved tear stability and ocular surface status in cases of inflammatory or SS-related dry eye. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01850979.

A review of guidelines for cross-cultural adaptation of questionnaires could not bring out a consensus.

OBJECTIVES: The aim of cross-cultural adaptation (CCA) of a questionnaire is to achieve equivalence between the original and adapted questionnaire. Here, we aimed to review the state of the art in CCA methods. STUDY DESIGN AND SETTING: We reviewed cross-disciplinary bibliographic databases for articles on methods and guidelines for CCA of questionnaires. Articles were first selected by their abstract and title, and then, we retrieved full-text English articles. References of selected articles were searched for additional relevant studies. RESULTS: We identified 31 guidelines and found no consensus in CCA methods. Most methods included use of committees, focus groups, and back translations. Evidence for the best methods is lacking, although clues indicate that back translation may not be mandatory. CONCLUSION: Several methods are available for CCA of questionnaires. According to experts only, most would achieve comparable results, and choosing one is a matter of preference and logistic. More evidence is needed to support recommendations. Adaptation and validation of a questionnaire are two different processes that should be distinguished and undertaken with care.

Enhancing the cross-cultural adaptation and validation process: linguistic and psychometric testing of the Brazilian-Portuguese version of a self-report measure for dry eye.

OBJECTIVES: To provide a reliable, validated, and culturally adapted instrument that may be used in monitoring dry eye in Brazilian patients and to discuss the strategies for the enhancement of the cross-cultural adaptation and validation process of a self-report measure for dry eye. METHODS: The cross-cultural adaptation process (CCAP) of the original Ocular Surface Disease Index (OSDI) into Brazilian-Portuguese was conducted using a 9-step guideline. The synthesis of translations was tested twice, for face and content validity, by different subjects (focus groups and cognitive interviews). The expert committee contributed on several steps, and back translations were based on the final rather than the prefinal version. For validation, the adapted version was applied in a prospective longitudinal study to 101 patients from the Dry Eye Clinic at the General Hospital of the University of São Paulo, Brazil. Simultaneously to the OSDI, patients answered the short form-36 health survey (SF-36) and the 25-item visual function questionnaire (VFQ-25) and underwent clinical evaluation. Internal consistency, test-retest reliability, and measure validity were assessed. RESULTS: Cronbach's alpha value of the cross-culturally adapted Brazilian-Portuguese version of the OSDI was 0.905, and the intraclass correlation coefficient was 0.801. There was a statistically significant difference between OSDI scores in patients with dry eye (41.15 ± 27.40) and without dry eye (17.88 ± 17.09). There was a negative association between OSDI and VFQ-25 total score (P < 0.01) and between the OSDI and five SF-36 domains. OSDI scores correlated positively with lissamine green and fluorescein staining scores (P < 0.001) and negatively with Schirmer test I and tear break-up time values (P < 0.001). CONCLUSION: Although most of the reviewed guidelines on CCAP involve well-defined steps (translation, synthesis/reconciliation, back translation, expert committee review, pretesting), the proposed methodological steps have not been applied in a uniform way. The translation and adaptation process requires skill, knowledge, experience, and a considerable investment of time to maximize the attainment of semantic, idiomatic, experiential, and conceptual equivalence between the source and target questionnaires. A well-established guideline resulted in a culturally adapted Brazilian-Portuguese version of the OSDI, tested and validated on a sample of Brazilian population, and proved to be a valid and reliable instrument for assessing patients with dry eye syndrome in Brazil.

Oral azithromycin for treatment of posterior blepharitis.

PURPOSE: To evaluate the effects of oral azithromycin in patients with posterior blepharitis. METHODS: Twenty-six eyes of 13 patients with posterior blepharitis diagnosed by a qualified ophthalmologist were enrolled in this study. Patients were instructed to use oral azithromycin 500 mg per day for 3 days in 3 cycles with 7-day intervals. Subjective clinical outcomes were graded and scored 1 day before and 30 days after the end of the treatment (53 days after initiating the treatment) based on severity scores of: (1) eyelid debris; (2) eyelid telangiectasia; (3) swelling of the eyelid margin; (4) redness of the eyelid margin; and (5) ocular mucus secretion. For the assessment of global efficacy, patients were asked by the investigator to rate the subjective symptoms (eyelid itching, ocular itching, eyelid hyperemia, ocular hyperemia, ocular mucus secretion, photophobia, foreign body sensation, and dry eye sensation) on a scale of 0 (no symptoms) to 5 (severe symptoms). Break-up time, Schirmer I test, corneal fluorescein staining score, and rose bengal staining score were also performed in all patients. RESULTS: All clinical outcomes scoring showed statistically significant improvement after oral azithromycin, except for eyelid swelling. Average subjective symptom grading improved statistically after treatment with oral azithromycin, except for eyelid hyperemia, photophobia, and foreign body sensation. Average tear film break-up time values showed statistically significant improvement after the treatment with oral azithromycin. No statistically significant improvement was observed on average values of Schirmer I test, corneal fluorescein staining score, and rose bengal staining score. CONCLUSIONS: The combination of multiple clinical parameters shown in this study supports the clinical efficacy of pulsed oral azithromycin therapy for the management of posterior blepharitis.

Two-year outcome of partial lacrimal punctal occlusion in the management of dry eye related to Sjögren syndrome.

PURPOSE: To analyze the influence of thermal partial punctal occlusion on the ocular surface of dry eye related to Sjögren syndrome. MATERIAL AND METHODS: Thirty-seven eyes of 19 patients (3 male and 16 female; 49.11 ± 14.33 years old) with keratoconjunctivitis sicca were enrolled in this study. Superior and inferior partial occlusion were performed in both eyes under topical anesthesia using thermal cautery with a sterile tip to obtain lacrimal punctum smaller than 0.5 mm. Schirmer I, break-up-time, diameter of lacrimal puncta, corneal fluorescein, and rose Bengal staining scores were analyzed before and after 24 weeks and after 24 months of the procedure. All measurements were performed under controlled climate. RESULTS: The average lacrimal punctum diameter before the procedure was 0.65 ± 0.134 mm. All lacrimal puncta were successfully reduced to less than 0.5 mm after 4 weeks of the procedure. The average Schirmer I test values improved statistically after 24 weeks and maintained stable after 24 months. Average break-up-time, rose Bengal, and fluorescein staining score values improved statistically after 24 weeks and improved even more after 24 months. Average Schirmer I test, break-up-time, rose Bengal, and fluorescein staining scores showed significant improvement (p < 0.0001) after 24 months of partial thermal punctal occlusion. CONCLUSION: Our study showed that reducing the punctum diameter to 0.5 mm can improve vital staining scores, break-up-time, and Schirmer I test in dry eye related to Sjögren syndrome.

Clinical treatment of ocular Demodex folliculorum by systemic ivermectin.

PURPOSE: To report clinical outcomes of the treatment of ocular Demodex folliculorum with oral ivermectin. DESIGN: Noncomparative, interventional case series. METHODS: Setting. Institutional. Study Population. Twenty-four eyes of 12 patients (3 male and 9 female; mean age ± standard deviation, 50.4 ± 21.0 years) with refractory posterior blepharitis with the presence of D. folliculorum in lash samples were enrolled in this study. Intervention. Patients were instructed to take 1 dose of oral ivermectin (200 µg/kg). All patients were instructed to repeat the treatment after 7 days. Main outcome measures. Tear meniscus height, Schirmer I test results, noninvasive tear film break-up time (BUT), quantification of the absolute number of D. folliculorum found in the lashes, and corneal fluorescein and rose bengal staining scores were obtained from all patients 1 day before and 28 days after treatment. RESULTS: Statistical improvement was observed in the absolute number of D. folliculorum found in the lashes after the treatment with oral ivermectin. Average values of Schirmer I test results and tear film break-up time improved statistically after the treatment of oral ivermectin. No statistical improvement was observed in average lacrimal meniscus height or value of corneal fluorescein and rose bengal staining after treatment with oral ivermectin. CONCLUSIONS: Ivermectin successfully reduced the number of D. folliculorum found in the lashes of patients with refractory blepharitis. Oral ivermectin may be very useful as a complement in the treatment of D. folliculorum infestation with ocular manifestation, especially in cases of unsuccessful treatment related to patient compliance.

Lesões expansivas da órbita: distribuição de casos com estudo histopatológico em 11 anos no Hospital das Clínicas da FMUSP / Orbital space-occupying lesions: an 11-year study of cases with histopathologic analysis seen at Hospital das Clínicas of FMUSP

OBJETIVO: Estudar a incidência das lesões expansivas orbitárias submetidas à biópsia em uma casuística de 11 anos no Hospital das Clínicas da FMUSP, e avaliar quais as principais especialidades envolvidas no diagnóstico e no tratamento de tais afecções. CASUÍSTICA E MÉTODOS: Solicitou-se ao setor de arquivos do hospital todos os casos de tumores e lesões de órbita submetidas à biópsia no período de 1993 a 2004. Dos 924 prontuários obtidos, 115 foram separados após análise dos dados segundo os resultados histopatológicos obtidos. Outros 111 pacientes foram obtidos por meio dos arquivos pessoais da patologista encarregada da Oftalmologia no Departamento de Patologia, dos quais 45 pacientes foram excluídos por coincidirem com a fonte anterior. Os dados foram contabilizados e comparados com os de outros serviços. RESULTADOS: Das 181 lesões orbitárias estudadas, 70 por cento eram primárias, 23 por cento eram secundárias, 6 por cento consistiam de metástases e linfomas e 1 por cento não foi classificada. Em relação à especialidade responsável diretamente pelo paciente, 72,37 por cento dos pacientes foram assistidos por oftalmologistas, 14,36 por cento por cirurgiões de cabeça e pescoço, 6,62 por cento por neurocirurgiões e 6,62 por cento por outros setores do hospital. CONCLUSÕES: As afecções orbitárias são atendidas em sua maioria pelos oftalmologistas especializados em tal área, e ao se incluir nesta casuística outras especialidades, nota-se um aumento no número de casos de lesões tumorais secundárias quando comparada ao de outros trabalhos realizados em serviços no exterior. Há necessidade de criar-se um registro confiável dos casos de lesões expansivas orbitárias nos serviços especializados brasileiros, e confirma-se o caráter multidisciplinar do objeto deste estudo.

PURPOSE: To report the incidence of orbital space-occupying lesions in an 11-year interval study of patients examined at the Hospital das Clínicas of FMUSP, and to evaluate which are the main specialties involved in the diagnosis and treatment of such conditions. METHODS: All cases of orbital space-occupying lesions in the period from 1993 to 2004 were revised. Of 924 obtained medical records, 155 were selected after histopathological analysis. Another 111 cases were gathered from the personal archives of a pathologist responsible for Ophthalmic Histopathology, from which 45 cases were excluded because they had already been included in the first source analysis. The data were analyzed and compared with the results from other institutions. RESULTS: Of the studied 181 orbital space-occupying lesions, 70 percent were primary, 23 percent secondary, 6 percent metastatic and lymphomas, and 1 percent was not classified. The most common specialties involved ophthalmologists in 72.37 percent of all 181 cases, head and neck surgeons in 14.36 percent, neurosurgeons in 6.62 percent, and others in 6.62 percent. CONCLUSIONS: The orbital mass lesions were treated mostly by an expert ophthalmologist. When other specialties were included, there was a modest increase in secondary tumor incidence when the final result was compared with previous studies on this subject. Our findings indicate that the creation of a trustworthy register of all orbital space-occupying lesions in Brazilian specialized services is necessary. The multidisciplinary character of the orbital mass lesions is corroborated by this review.

[Orbital space-occupying lesions: an 11-year study of cases with histopathologic analysis seen at Hospital das Clínicas of FMUSP]. / Lesões expansivas da órbita: distribuição de casos com estudo histopatológico em 11 anos no Hospital das Clínicas da FMUSP.

PURPOSE: To report the incidence of orbital space-occupying lesions in an 11-year interval study of patients examined at the Hospital das Clínicas of FMUSP, and to evaluate which are the main specialties involved in the diagnosis and treatment of such conditions. METHODS: All cases of orbital space-occupying lesions in the period from 1993 to 2004 were revised. Of 924 obtained medical records, 155 were selected after histopathological analysis. Another 111 cases were gathered from the personal archives of a pathologist responsible for Ophthalmic Histopathology, from which 45 cases were excluded because they had already been included in the first source analysis. The data were analyzed and compared with the results from other institutions. RESULTS: Of the studied 181 orbital space-occupying lesions, 70% were primary, 23% secondary, 6% metastatic and lymphomas, and 1% was not classified. The most common specialties involved ophthalmologists in 72.37% of all 181 cases, head and neck surgeons in 14.36%, neurosurgeons in 6.62%, and others in 6.62%. CONCLUSIONS: The orbital mass lesions were treated mostly by an expert ophthalmologist. When other specialties were included, there was a modest increase in secondary tumor incidence when the final result was compared with previous studies on this subject. Our findings indicate that the creation of a trustworthy register of all orbital space-occupying lesions in Brazilian specialized services is necessary. The multidisciplinary character of the orbital mass lesions is corroborated by this review.

[Subconjunctival deposit of silicone oil after vitreoretinal surgery]. / Depósito subconjuntival de óleo de silicone após cirurgia vitreorretiniana.

PURPOSE: To assess the histopathological findings of conjunctival specimens from patients submitted to vitreoretinal surgery with intraocular silicone oil injection. METHODS: Prospective analyses of 30 eyes of 30 patients were evaluated. Before the patients underwent removal of the intraocular silicone oil, conjunctival excision was performed and submitted to histopathologic examination. RESULTS: The presence of empty spaces corresponding to silicone oil location was positive in 10 (33%) specimens. The presence of inflammatory cells, vascular congestion, leukostasis, lymphocyte and monocyte infiltrates were positive in 27 (90%) specimens. The presence of silicone oil was positive in 10 (33%) specimens. Therefore, in those patients who undergo vitreoretinal surgery, silicone oil may be present in the conjunctiva or subconjunctival space, even if biomicroscopic examination seems to be normal. According to our knowledge, this is the first study with the purpose to assess the histopathological findings of conjunctival specimens from patients submitted to vitreoretinal surgery with intraocular silicone oil injection. CONCLUSION: Ophthalmologists should be aware of this possible complication after intraocular use of silicone oil after vitreoretinal surgery.

[Idiopathic orbital inflammation with extraorbital extension: case report]. / Inflamação idiopática da órbita com extensão extra-orbital: relato de caso.

The authors report a case of a patient with idiopathic orbital inflammation with extension beyond the orbit. Biopsy was performed to confirm the diagnosis of idiopathic orbital inflammation and computed tomography demonstrated the extraorbital extension. Treatment with methotrexate and radiotherapy was used.

Depósito subconjuntival de óleo de silicone após cirurgia vitreorretiniana / Subconjunctival deposit of silicone oil after vitreoretinal surgery

OBJETIVO: Comprovar a presença do óleo de silicone no espaço subconjuntival de pacientes submetidos previamente à cirurgia vitreorretiniana por meio de estudo histopatológico das amostras conjuntivais obtidas, nos quais o exame biomicroscópico não foi capaz de comprovar sua presença. Determinar qual a incidência da presença do óleo de silicone no espaço subconjuntival em uma série de casos e quais implicações clínico-patológicas. MÉTODOS: Estudo prospectivo em 30 olhos de 30 pacientes. Foram incluídos no estudo os pacientes que haviam sido submetidos previamente à cirurgia vitreorretiniana com implante intra-ocular de óleo de silicone e que possuíssem indicação para retirada do óleo de silicone e que não apresentassem ao exame biomicroscópico sinais da presença do óleo de silicone no espaço subconjuntival. Após sua retirada, a amostra era encaminhada para análise histopatológica pelo método de hematoxilina-eosina. RESULTADOS: Foi observada a presença de espaços vazios correspondentes às áreas de localização do óleo de silicone, removido durante processamento histológico, em 10 (33 por cento) amostras. Observou-se também a presença de sinais inflamatórios na substância própria caracterizada por congestão vascular, leucostase e infiltrado linfomononuclear em 27 (90 por cento) amostras. CONCLUSÃO: Portanto, em pacientes submetidos ao implante intra-ocular do óleo de silicone, devemos suspeitar que o óleo esteja presente no espaço subconjuntival, mesmo que o exame biomicroscópico pareça normal.

PURPOSE: To assess the histopathological findings of conjunctival specimens from patients submitted to vitreoretinal surgery with intraocular silicone oil injection. METHODOS: Prospective analyses of 30 eyes of 30 patients were evaluated. Before the patients underwent removal of the intraocular silicone oil, conjunctival excision was performed and submitted to histopathologic examination. RESULTS: The presence of empty spaces corresponding to silicone oil location was positive in 10 (33 percent) specimens. The presence of inflammatory cells, vascular congestion, leukostases, lymphocyte and monocyte infiltrates were positive in 27 (90 percent) specimens. The presence of silicone oil was positive in 10 (33 percent) specimens. Therefore, in those patients who undergo vitreoretinal surgery, silicone oil may be present in the conjunctiva or subconjunctival space, even if biomicroscopic examination seems to be normal. According to our knowledge, this is the first study with the purpose to assess the histopathological findings of conjunctival specimens from patients submitted to vitreoretinal surgery with intraocular silicone oil injection. CONCLUSION: Ophthalmologists should be aware of this possible complication after intraocular use of silicone oil after vitreoretinal surgery.